1 |
de Koning C. Fatigue syndrome in sarcoidosis. Medicom Conference Report NLC 2022 2022. [DOI: 10.55788/5bf9d2d5] [Reference Citation Analysis]
|
2 |
Harman NL, Gorst SL, Williamson PR, Barnathan ES, Baughman RP, Judson MA, Junk H, Kampstra NA, Sullivan EJ, Victorson DE, Walton M, Al-Hakim T, Nabulsi H, Singh N, Grutters JC, Culver DA. Scout - sarcoidosis outcomes taskforce. A systematic review of outcomes to inform the development of a core outcome set for pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2021;38:e2021034. [PMID: 34744426 DOI: 10.36141/svdld.v38i3.10737] [Reference Citation Analysis]
|
3 |
Atkins C, Jones A, Clark AB, Stockl A, Fordham R, Wilson AM. Feasibility of investigating methylphenidate for the treatment of sarcoidosis-associated fatigue (the FaST-MP study): a double-blind, parallel-arm randomised feasibility trial. BMJ Open Respir Res 2021;8:e000814. [PMID: 34020962 DOI: 10.1136/bmjresp-2020-000814] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
4 |
Gvozdenovic BS, Mihailovic-Vucinic VV, Vukovic MH, Stjepanovic MI, Buha I, Mihailovic SV, Maric NB. Predictors of cough-specific and generic quality of life in sarcoidosis patients. Sarcoidosis Vasc Diffuse Lung Dis 2020;37:158-68. [PMID: 33093779 DOI: 10.36141/svdld.v37i2.9234] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
|